You’ve likely read or heard about your gut bacteria, and how scientists and clinicians are developing a much greater understanding of the effects this additional “other organ” on our health and wellness. It’s truly amazing that there are more bacteria living in our gut than there are cells that make up our body! These bacteria have an enormous impact on the development of our immune systems. Read more
We are excited to learn that based on the ten years of clinical trials at UVA, a new startup, Type Zero, is taking the inControl Diabetes Management Platform — which is the software running the UVA AP — to the next level. Read more
This is an important study because really it’s the first to show a defined effect between the development of the microbiome in infancy and the diagnosis of type 1 diabetes. It opens doors to further questions. What I think will come out of this are targeted, prophylactic treatments rather than something that’s meant to cure disease. Scientists need to dig further into what are the important species that are protective in these children. Read more
The study could have important implications for identifying the disease at a very early stage, delaying its onset or even preventing it altogether. Dr. Julia Greenstein, vice president of discovery research at JDRF, which helped fund the study, says that the work is very preliminary, but points toward strategies for prevention that haven’t yet been explored. Read more
Faustman says that her work has raised the ire of some scientists and organizations for two reasons: It runs counter to the prevailing research emphasis to either prevent type 1 diabetes, or reverse it in people who have been recently diagnosed with diabetes and, at the time, ran into a stiff political headwind from embryonic stem cell researchers. Read more
Todd Hobbs, the chief medical officer for North America at Novo Nordisk, knows diabetes from all angles: as a patient; as an endocrinologist (for ten years he ran a clinical practice focused on patients of all ages with diabetes); as an executive at a pharmaceutical company working to develop new treatments (he’s worked at Novo Nordisk since 2004); and as a parent (one of his six sons was diagnosed with type 1 at age five) Read more
Scientists have successfully reversed type 1 diabetes in mice by using adult stem cells and cell surface molecular engineering to reduce the destruction of insulin-producing islet cells.
The key to the breakthrough was introducing adult stem cells… Read more
Researchers with the Janssen Pharmaceutical Companies of Johnson & Johnson recently announced a plan to prevent type 1 diabetes by intercepting the disease in its earliest stages and stopping its development before the onset of symptoms.
Researchers at MIT successfully tested an engineered “smart insulin” on mice that reacts to blood sugar levels. “To make insulin that is glucose responsive is something that we believe will significantly improve blood sugar control in people with diabetes,” said … Read more
The benefit of making mature beta cells entirely in the dish is that they may be a useful resource for research aimed at understanding the causes of diabetes (both Type 1 and Type 2) as well as developing new therapeutic strategies for diabetes. Moreover, ultimately, mature beta cells may prove to be better than pancreatic progenitor cells for transplant into patients with diabetes. Read more